Although imatinib revolutionized the management of chronic myeloid leukemia (CML),
recent data indicate a transformation in the treatment approach likely in the near future. For …

Chronic myeloid leukemia (CML) is a progressive and often fatal myeloproliferative disorder.
The introduction of imatinib, a tyrosine kinase inhibitor (TKI) specific for BCR-ABL, was a …

As the first clinically successful tyrosine kinase inhibitor (TKI), imatinib pioneered a new
approach to treating patients with cancer. Dramatic results from chronic myeloid leukemia …

The introduction of imatinib mesylate, a Bcr-Abl1 tyrosine kinase inhibitor (TKI), has
revolutionized the treatment of chronic myeloid leukemia (CML). By directly targeting the Bcr …

Rational design of tyrosine kinase inhibitors, such as imatinib, against leukemogenic Bcr‐
Abl kinase has resulted in unprecedented responses and survival rates in patients with …

The clinical outcome for patients with chronic myelogenous leukemia (CML) has changed
dramatically in the past 15 years. This has been due to the development of tyrosine kinase …

Imatinib is broadly used in the frontline treatment of chronic myeloid leukemia (CML).
Although long-term safety and efficacy have been established, some patients will not …

Although imatinib has been used as frontline therapy for chronic myeloid leukemia (CML) for
nearly a decade, current debate is focused on the incorporation of newer tyrosine kinase …

The BCR-ABL inhibitor imatinib revolutionized the treatment of chronic myeloid leukemia
(CML). However, resistance and intolerance to imatinib have emerged as substantial clinical …

Background: Imatinib has been found to substantially improve outcomes in patients with
chronic myeloid leukemia (CML) compared with previously available therapies. However, its …